Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8101 to 8115 of 9008 results

  1. Pelareorep for treating metastatic or recurrent squamous cell carcinoma of the head and neck after platinum-based chemotherapy ID940

    Discontinued Reference number: GID-TA10397

    Technology appraisal guidance
    Discontinued

  2. Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682]

    Discontinued Reference number: GID-TA10609

    Technology appraisal guidance
    Discontinued

  3. Breast cancer (HER2-negative, BRCA-mutation, unresectable) - niraparib [ID1084]

    Discontinued Reference number: GID-TA11178

    Technology appraisal guidance
    Discontinued

  4. Ridaforolimus for the maintenance treatment of metastatic soft tissue or bone sarcoma [ID415]

    Discontinued Reference number: GID-TAG431

    Technology appraisal guidance
    Discontinued

  5. Rituximab for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs [ID333]

    Discontinued Reference number: GID-TAG418

    Technology appraisal guidance
    Discontinued

  6. Everolimus for the treatment of prophylaxis of organ rejection in cardiac transplantation [ID114]

    Discontinued Reference number: GID-TAG232

    Technology appraisal guidance
    Discontinued

  7. Pancreatic cancer - capecitabine [ID389]

    Discontinued Reference number: GID-TAG394

    Technology appraisal guidance
    Discontinued

  8. Bevacizumab in combination with chemotherapy for the second line treatment of HER2 negative metastatic breast cancer [ID488]

    Discontinued Reference number: GID-TAG432

    Technology appraisal guidance
    Discontinued

  9. Rivaroxaban for the prevention of venous thromboembolism in people hospitalised for acute medical conditions [ID463]

    Discontinued Reference number: GID-TAG427

    Technology appraisal guidance
    Discontinued

  10. Masitinib for treating relapsed or refractory peripheral T-cell non-Hodgkin lymphoma [ID1125]

    Discontinued Reference number: GID-TA11173

    Technology appraisal guidance
    Discontinued

  11. Durvalumab with tremelimumab for treating squamous cell head and neck cancer after platinum-based chemotherapy [ID1144]

    Discontinued Reference number: GID-TA10474

    Technology appraisal guidance
    Discontinued

  12. Prostate cancer (hormone refractory) - atrasentan [ID390]

    Discontinued Reference number: GID-TAG379

    Technology appraisal guidance
    Discontinued

  13. Ipilimumab for the adjuvant treatment of completely resected stage IV or high risk stage III melanoma [ID721]

    Discontinued Reference number: GID-TAG479

    Technology appraisal guidance
    Discontinued

  14. Obinutuzumab with CHOP chemotherapy for untreated CD20-positive diffuse large B-cell non-Hodgkin's lymphoma [ID1021]

    Discontinued Reference number: GID-TA11119

    Technology appraisal guidance
    Discontinued

  15. Nitazoxanide for treating the common cold in people 12 years and over [ID4049]

    Discontinued Reference number: GID-TA11128

    Technology appraisal guidance
    Discontinued